Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis

Reuters2025-12-31

<a href="https://laohu8.com/S/01177">Sino Biopharm</a> Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis

Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in the Phase III clinical trial of TDI01, a highly selective ROCK2 inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF). This marks the first time a highly selective ROCK2 inhibitor has entered Phase III clinical trials for IPF globally. TDI01 is designed to precisely target the angiocrine system, addressing vascular leakage, fibrosis, inflammation, and immune dysregulation associated with IPF. The company aims to accelerate clinical development of TDI01 in hopes of providing a more effective and safer treatment option for patients. No scientific research results have been presented yet; the announcement pertains to the progress in clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251231-11972158), on December 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595728689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 12:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595728689","market":"fut","top_or_hot":-1,"title":"Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01177\">Sino Biopharm</a> Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Limited has announced the completion of enrollment of the first patient in the Phase III clinical trial of TDI01, a highly selective ROCK2 inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF). This marks the first time a highly selective ROCK2 inhibitor has entered Phase III clinical trials for IPF globally. TDI01 is designed to precisely target the angiocrine system, addressing vascular leakage, fibrosis, inflammation, and immune dysregulation associated with IPF. The company aims to accelerate clinical development of TDI01 in hopes of providing a more effective and safer treatment option for patients. No scientific research results have been presented yet; the announcement pertains to the progress in clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a> Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251231-11972158), on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-31 12:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01177\">Sino Biopharm</a> Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Limited has announced the completion of enrollment of the first patient in the Phase III clinical trial of TDI01, a highly selective ROCK2 inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF). This marks the first time a highly selective ROCK2 inhibitor has entered Phase III clinical trials for IPF globally. TDI01 is designed to precisely target the angiocrine system, addressing vascular leakage, fibrosis, inflammation, and immune dysregulation associated with IPF. The company aims to accelerate clinical development of TDI01 in hopes of providing a more effective and safer treatment option for patients. No scientific research results have been presented yet; the announcement pertains to the progress in clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a> Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251231-11972158), on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL8FGlts:1","article_id":"2595728689","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595728689","pubTimestamp":1767155502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in the Phase III clinical trial of TDI01, a highly selective ROCK2 inhibitor developed for the treatment of idiopathic pulmonary fibrosis . This marks the first time a highly selective ROCK2 inhibitor has entered Phase III clinical trials for IPF globally. TDI01 is designed to precisely target the angiocrine system, addressing vascular leakage, fibrosis, inflammation, and immune dysregulation associated with IPF. The company aims to accelerate clinical development of TDI01 in hopes of providing a more effective and safer treatment option for patients. No scientific research results have been presented yet; the announcement pertains to the progress in clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1589":"北水核心资产","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药"},"translate_title":"中国生物制药TDI01治疗肺纤维化III期试验首例患者入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis\n    \n\nSino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in the Phase III clinical trial of TDI01, a highly selective ROCK2 inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF). This marks the first time a highly selective ROCK2 inhibitor has entered Phase III clinical trials for IPF globally. TDI01 is designed to precisely target the angiocrine system, addressing vascular leakage, fibrosis, inflammation, and immune dysregulation associated with IPF. The company aims to accelerate clinical development of TDI01 in hopes of providing a more effective and safer treatment option for patients. No scientific research results have been presented yet; the announcement pertains to the progress in clinical development.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251231-11972158), on December 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595728689","isCrawlerRequest":true}